Mxi1 belongs to the Myc/Max/Mad network of proteins that have been implicated in the control of multiple aspects of cellular behavior. Previously, we had reported that the mouse mxi1 gene gives rise to two distinct transcript forms that can encode proteins with dramatically different functional abilities. The Mxi1-SR protein (here termed Mxi1-SRb) can interact with Sin3/histone deacetylase and function as a potent transcriptional repressor and growth suppressor, while the Mxi1-WR protein lacks these activities. Here, we describe a new mxi1-derived transcript form (termed mxi1-SRa) whose expression is governed by its own promoter, resulting in a spatiotemporally distinct expression profile from that of the highly related mxi1-SRb form. Moreover, the Mxi1-SRa protein product, with its unique Sin3 interacting domain, has a greater affinity than its Mxi1-SRb counterpart for the Sin3 adapter proteins as well as an enhanced potential for transcriptional repression in transient reporter assays. Our identification of this novel Mxi1 isoform that results from alternative 5 0 exon usage adds an additional layer of complexity to the Mad/Mxi1 family. In addition, our findings warrant re-evaluation of mxi1 expression patterns on the cellular level and its status in human cancer samples, with a renewed focus on the distinct isoforms.
Introduction
Members of the Myc/Max/Mad network have been implicated as important regulators of many aspects of cellular behavior (reviewed in Grandori et al., 2000; Baudino and Cleveland, 2001; Luscher, 2001; Oster et al., 2002) . These proteins are unified through their having related basic region helix-loop-helix/leucine zipper (bHLH/LZ) motifs that impart upon them the abilities to heterodimerize and to bind to DNA in a sequence-specific manner. The Max protein is central to the network as the obligate DNA binding partner for the Myc family proteins (c-Myc, N-Myc, and L-Myc), for the Mad family proteins (Mad1, Mxi1 (also known as Mad2), Mad3, and Mad4), and for the more recently characterized Mnt/Rox and Mga proteins. By heterodimerizing with these other members of the network, Max (or, for a subset of these members, a Max-related protein Mlx) can effect their functional activities in the regulation of gene expression. These functional activities can be generalized as: (i) transactivation and repression for Myc/Max; (ii) repression for Mad/Max and Mnt/Max; and (iii) transactivation for Mga/Max (reviewed in Grandori et al., 2000; Baudino and Cleveland, 2001; Luscher, 2001 ; also see Mao et al., 2003 for recent evidence of Max participating in Myc repression function).
By virtue of the ability of the Mad family proteins to compete with Myc for both Max and for downstream genetic targets bearing the Myc/Max consensus E-box (CANNTG) site, the Mad proteins have been promoted as Myc antagonists (as has the Mnt protein). This antagonism between Myc and Mad extends beyond these protein families per se to a subset of the co-factors they recruit for the regulation of gene expression. More specifically, Myc has been shown to engage histone acetyltransferases (HATs) (McMahon et al., 2000) , histone modifying enzymes that have traditionally been linked to transcriptional activation since they can loosen local chromatin architecture (reviewed in Carrozza et al., 2003) . The finding that Myc can recruit HATs has led to a model in which Myc transactivation results in part from its facilitating access for other, possibly more potent or gene-specific, transcriptional activators (reviewed in Grandori et al., 2000) . In contrast to Myc associating with HATs, the Mad family proteins (and Mnt) have been shown to engage histone deacetylases (HDACs), among other co-repressors, via the Sin3 adapter proteins (Alland et al., 1997; Laherty et al., 1997) . Histone deacetylases participate in the silencing of gene expression (reviewed in Thiagalingam et al., 2003) and are recruited via Sin3 to a variety of other transcriptional repressors as well (reviewed in Knoepfler and Eisenman, 1999) . The recruitment of Sin3/HDAC by the Mad proteins (and Mnt) is mediated by a conserved SID (Sin3 interacting domain) present in their amino terminal regions. These SIDs have been shown to be modular transrepression domains (Ayer et al., 1996; Harper et al., 1996) , and are required for the potent activities of the Mad family proteins in functional assays. These assays include reporter assays wherein the Mad proteins act as transcriptional repressors, and rat embryo fibroblast (REF) cooperation assays (Land et al., 1983) wherein the Mad proteins act as suppressors of Myc/Ras co-transformation (reviewed in Grandori et al., 2000; Baudino and Cleveland, 2001; Luscher, 2001) .
The demonstrated ability of the Mad family proteins to function as growth suppressors in the REF and other cell culture-based assays, coupled with their induced expression during differentiation and their chromosomal mapping to hot-spots for deletion in human cancers, has led to the hypothesis that they may be bona fide tumor suppressor proteins (reviewed in Grandori et al., 2000; Baudino and Cleveland, 2001; Luscher, 2001 ). This hypothesis is supported by several observations including mutations/allele specific loss of MXI1 in human prostate cancers and melanomas (Prochownik et al., 1998; Ariyanayagam-Baksh et al., 2003) and downregulation of MXI1 transcript levels in testicular tumors (Skotheim et al., 2002) . In addition, Mxi1-deficient mice displayed increased susceptibility to tumorigenesis induced by carcinogens or by the concomitant loss of the INK4a/ARF tumor suppressor locus (Schreiber-Agus et al., 1998) . Notwithstanding, collectively the Mad family knockout mice did not present with dramatic tumor-prone phenotypes, an outcome that is often attributed to functional redundancy among the four members of this family (reviewed in Pirity et al., in press; Baudino and Cleveland, 2001) . Alternatively, the possibility that the related Mnt protein may be playing a more significant role in the negative regulation of proliferation (and in Myc antagonism) is supported by the cancer predisposition of Mnt conditionally deficient mice (Hurlin et al., 2003) . With respect to the issue of functional redundancy among the Mad family, in the majority of comparative studies performed to assess their functions and interactions, the four members are indistinguishable. One notable exception is the finding that only Mad1 and Mad4 can interact with Mlx, suggesting that the secondary network of Mad interacting proteins may diversify the functions of this family . Differences between the Mad family members become readily apparent in studies that have examined their spatiotemporal expression patterns in developing organs/embryos or cell culture-based differentiation systems (e.g. see Hurlin et al., 1995; Queva et al., 1998; Luo et al., 2001 ). These differences in expression patterns could provide the basis for the preservation of the individual members as distinct sequences throughout mammalian evolution -a theory that also has been invoked for the three myc family genes (reviewed in Pirity et al., in press ).
Previously, we had reported that the mouse mxi1 gene gives rise to two distinct transcript forms that can encode proteins with dramatically different functional abilities (Schreiber-Agus et al., 1995) . The Mxi1-SR protein (here termed Mxi1-SRb) possesses a SID and functions as a potent transcriptional repressor and growth suppressor. In contrast, the Mxi1-WR protein lacks this domain and activity. Here, we show that an additional mxi1-derived transcript form exists (termed mxi1-SRa) that has the potential to encode a protein with a SID distinct from the one present in Mxi1-SRb. Despite being highly related both structurally and functionally, the newly recognized Mxi1-SRa isoform exhibits a greater affinity for the Sin3 adapter proteins and an enhanced potential for transcriptional repression in transient reporter assays when compared with its Mxi1-SRb counterpart. In addition, the mxi1-SRa and mxi1-SRb forms are governed by distinct promoters and exhibit spatiotemporally distinct expression profiles, suggesting that these proteins may have distinct tissueor stage-specific functions. Our identification of this novel mxi1 isoform adds an additional layer of redundancy and complexity to the Mad/Mxi1 family. Moreover, our findings warrant re-evaluation of mxi1 expression patterns on the cellular level and its status in human cancer samples, with a renewed focus on the distinct isoforms and their potential functional similarities and differences.
Results
The mouse mxi1 genomic locus gives rise to at least three different mRNA isoforms that are capable of encoding distinct protein isoforms An analysis of the mouse mxi1 genomic locus using programs that predict gene structures and products (e.g. February 2003 mouse genome assembly (UCSC version mm3) (http://genome.ucsc.edu/)) revealed that there are numerous putative exons for which corresponding expressed sequence tags (ESTs) have been identified (Figure 1a) . Several of these exons contribute to the mouse mxi1-SRb (formerly known as mxi1-SR) and mxi1-WR transcript forms that we have described previously (Schreiber-Agus et al., 1995) (specifically exons 2, 3, and 6-10 for mxi1-SRb, and exons 5 and 6-10 for mxi1-WR) (Figure 1a and b) (GenBank Accession Number L38822 for mxi1-SRb and GenBank Accession Number L38821 for mxi1-WR). Other exons, namely exons 1 or 4, can be found contiguous with exons 6-10 in sequences present in the mouse EST database (see Note). We have designated the mxi1-derived transcript form that contains the exon 1 sequence as mxi1-SRa (Figure 1b) for reasons that will become apparent below. As an aside, there are additional putative internal exons predicted for the mxi1 genomic locus for which corresponding ESTs have been identified, suggesting that additional transcript isoforms may exist as well (Dugast-Darzacq and Schreiber-Agus, unpublished observations).
Based on the position of the 5 0 -most ATGs preceded by stop codons in the three mouse mxi1 mRNA isoforms shown in Figure 1b , we have determined the putative proteins these isoforms could encode as shown schematically in Figure 1c . Of note, the proteins predicted to be encoded by the mxi1-SRb and mxi1-WR transcript forms are 100% identical in amino-acid sequence with the exception of a 36 amino-acid (aa) extension on the amino terminal end of the Mxi1-SRb protein (Schreiber-Agus et al., 1995). This extension, now known to encode a SID (for Sin3 interacting domain), has been shown by us and others to mediate recruitment of the Sin3 adapter protein and its associated co-repressors. This region also is critical for Mxi1 (and other Mad family members) repression and growth suppression activities (reviewed in Grandori et al., 2000; Baudino and Cleveland, 2001 ; Luscher, Figure 1 The mxi1 gene can give rise to multiple mRNA transcripts that encode different protein isoforms. (a) The genomic organization of the mouse mxi1 locus (mxi1-gDNA) is shown. The exons (numbered 1-10) are represented by boxes, whereas the introns are represented by lines. Note that this locus is not drawn to scale, but double slashes through the introns between exons 1 and 2, 6 and 7, and 7 and 8 indicate the presence of large introns (18.7, 15, and 22.8 kb, respectively) . (b) Three of the mouse mxi1 mRNA transcript forms resulting from alternative 5 0 exon usage are shown. Note that the mxi1-SRb form was known previously as mxi1-SR (Schreiber- Agus et al., 1995) . (c) Schematic representation of the different protein isoforms capable of being encoded by the transcript forms depicted in (b). Note that the SRa and SRb forms are extended on their amino termini relative to the WR form, with the aminoacid sequences of these extensions shown below. The SRa extension can be subdivided into two portions: aa 1-61 represent a prolinerich domain of unknown function, while aa 62-103 are highly homologous to the SRb amino terminal extension and encode a putative SID (underlined). SID ¼ Sin3 interaction domain, BR ¼ basic region, HLH ¼ helix-loop-helix; CT ¼ carboxyl terminus, NT ¼ amino terminus. (d) Western blotting analysis of nuclear extracts and lysates from HeLa and 293T cells using the polyclonal anti-Mad2 (alternative name for Mxi1) antibody (Santa Cruz #1042). The MXI1-SRa band is indicated by a closed arrow, the MXI1-SRb band is indicated by an open arrow, and a nonspecific band migrating below the MXI1-SRb band is marked by an asterisk. The designation of the bands as the endogenous MXI1-SRa and MXI1-SRb proteins was further supported by the identical migration of transfected, nontagged versions of these proteins in 293T lysates (see transfection lanes for Mxi1-SRa and Mxi1-SRb). The specificity of the antibody was further validated by the altered migration of transfected MYC-tagged versions of Mxi1-SRa and Mxi1-SRb (right panel). Note that the endogenous MXI1-SRa band is enriched in nuclear extracts relative to lysates from both 293T and HeLa cells, while the endogenous MXI1-SRb band is detectable in nuclear extracts from 293T cells only. These results are consistent with those obtained on the RNA level by RT-PCR in which the MXI1-SRa transcript was readily detected in both HeLa and 293T cells and the MXI1-SRb in 293T cells only (data not shown). NE ¼ nuclear extract, lys ¼ lysate, NS ¼ nonspecific 2001). Interestingly, the protein predicted to be encoded by the new mxi1-SRa transcript form is 100% identical to the predicted Mxi1-WR protein, with the exception of an 103 aa amino terminal extension that encodes a putative SID (based on amino-acid composition van Ingen et al., 2004 , and see more below), as well as a novel domain (see Figure 1c) . This novel domain (aa 1-61) has a proline-rich composition reminiscent of transactivation domains, and it bears some homology to a proline-rich region found in the Max-associated protein Mnt (Hurlin et al., 1997) . Of note, the MXI1-SRa and MXI1-SRb transcript forms also are present in humans, as is a human transcript form that is capable of encoding an MXI1 protein lacking a SID domain (GenBank Accession Number BC035128 for MXI1-SRa; GenBank Accession Number L07648 for MXI1-SRb; GenBank Accession Number BC012907 for a form capable of encoding an Mxi1 protein lacking a SID). The predicted mouse and human Mxi1-SRa proteins are 95% identical on the amino-acid level, and the predicted mouse and human Mxi1-SRb proteins are also 95% identical. As shown in Figure 1d , we have been able to detect the endogenous Mxi1-SRa and/or Mxi1-SRb proteins in several commonly used cell types examined, using an antibody generated to the conserved carboxyl terminus of both isoforms. Specifically, Mxi1-SRa was readily detectable in lysates, and highly enriched in nuclear extract preparations, from HeLa and 293T cells; Mxi1-SRb was detectable in nuclear extracts from 293T cells only. The designation of these bands as the endogenous Mxi1-SRa and Mxi1-SRb proteins was further supported by the identical migration of transfected, nontagged versions of these proteins in 293T lysates (Figure 1d , transfected lanes for Mxi1-SRa and Mxi1-SRb; transfected lanes for MYCtagged versions of Mxi1-SRa and Mxi1-SRb are shown in the right panel for comparison). This suggests that the two SR protein isoforms indeed exist in vivo and that there may be selective pressure to maintain these distinct isoforms as unique sequences across mammalian evolution. Finally, the SID-less mouse (i.e. Mxi1-WR) and human protein isoforms have not yet been observed endogenously, raising the possibility that they may be highly specialized forms that are made only in certain spatiotemporal or disease-related contexts.
Differential expression patterns of the mxi1 transcript isoforms in newborn and adult mouse tissues and developing mouse embryos
To assess the specific expression patterns of the various mRNA isoforms and their comparative levels, we revisited an RNase protection assay performed previously upon total RNA isolated from a panel of newborn and adult mouse tissues (shown in Figure 2b and referred to in Schreiber- Agus et al., 1995) . The riboprobe employed for this assay was derived from the mouse mxi1-WR cDNA (Schreiber-Agus et al., 1995) and was composed of mxi1-WR-specific sequences (exon 5) as well as sequences that are also common to the other mRNA isoforms (exon 6) (see Figure 2a ). As shown in Figure 2b , the mxi1-WR-specific RNase protection product was detected in newborn kidney only (top panel, lane 3), albeit at very low levels. Longer exposures of this gel, or the probing of polyA þ mRNA by RNase protection with the same probe, revealed that mxi1-WR transcripts are also detectable, albeit in very low amounts, in other newborn/adult tissues including intestine, brain, and liver (data not shown). As the probe employed for these RNase protection assays contained sequences that are common to other mxi1 isoforms, putative protected bands were observed for these as well and at levels markedly higher than those that were mxi1-WR-specific ( Figure 2b , bottom panel). Notably, bands that were likely to be mxi1-SRb-and mxi1-SRa-specific (based on product size predicted from the identity between each of these and mxi1-WR in the exon 6 region and the nucleotides just upstream of exon 6) were distinguishable on these gels, and displayed tissue and stage-specific differences in their representation ( Figure 2b ).
To validate that these protected bands indeed represented mxi1-SRb and mxi1-SRa, we selected several adult tissues in which there were marked differences in representation of these lower bands and performed real time reverse transcriptase-polymerase chain reaction (RT-PCR) assays with primers that were capable of amplifying these isoforms specifically (namely a primer in exon 1 for amplification of mxi1-SRa or a primer in exon 3 for amplification of mxi1-SRb, combined with a common downstream primer in exon 6). PCR products of the expected sizes and expected sequence based on the database information for these isoforms were obtained for the two primer combinations. Consistent with what was predicted based on the RNase protection assay results, real time RT-PCR analysis revealed that the mxi1-SRa form predominated in the adult intestine, while the mxi1-SRb form predominated in the adult liver and the kidney (Figure 2c ). Finally, we extended the real time RT-PCR analysis to mouse embryos at various stages of development as well ( Figure 2d ). These studies showed that the mxi1-SRa form was expressed at significantly higher levels than the mxi1-SRb form throughout embryogenesis. Specifically, the levels of the mxi1-SRa form are approximately 30-fold greater than those of mxi1-SRb during the embryonic day (E) 8.5-10.5 timeframe, and this difference decreases to six-fold during later stages of differentiation due to an increase therein of mxi1-SRb transcripts.
The observed differences in expression patterns/levels of the mxi1-SRa and mxi1-SRb isoforms suggested that these transcripts may be subject to differential regulation by mechanisms affecting their rate of transcription, splicing, turnover, etc. As a first attempt to address whether their expression could be governed by independent promoters, we analysed the genomic regions flanking the 5 0 ends of the collection of mRNAs/ESTs corresponding to the mouse mxi1-SRa or mxi1-SRb transcript forms. Notably, these genomic regions are marked by CpG islands (data not shown) that traditionally are found at or near transcriptional start sites (Antequera and Bird, 1999) . Within the human MXI1 locus, CpG islands also are found flanking the 5 0 -most sequences of the corresponding MXI1-SRa or MXI1-SRb transcript forms. Indeed, the promoter region for the human MXI1-SRb transcript form has been described (Benson et al., 1999) and co-maps with the CpG island in that region. In light of the fact that the human MXI1-SRb transcript form is driven by this promoter that is quite distal to the MXI1-SRa 5 0 most sequences (B18.5 kb), we predicted that human MXI1-SRa transcription also could be governed by its own promoter (and that the same would hold true for the two mouse SR forms as well). We chose to focus on the putative human, as opposed to mouse, MXI1-SRa promoter region since (i) the human MXI1-SRb promoter region had been cloned previously (Benson et al., 1999) , and (ii) cloning the human promoter would allow for future assessment of whether it may be affected during the pathogenesis of human cancers. To define precisely the 5 0 end of the human MXI1-SRa transcript, we performed 5 0 Rapid Amplification of cDNA Ends (RACE) analysis upon HeLa total RNA that allowed for the recovery of a 432 bp product ( Figure 3a) . Then, the CpG-rich region immediately 5 0 was cloned by PCR on human genomic DNA and assessed for promoter activity in reporter assays. As shown in Figure 3b , a 187 bp flanking region, when cloned into the pGL3-Basic vector that lacks promoter and enhancer sequences (Promega), was able to drive luciferase expression to a similar extent to the positive control reporter construct (GAL4tkluc construct bearing a minimal tk (thymidine kinase) promoter) ( Figure 3b ). In addition, the construct containing the human MXI1-SRa minimal promoter and the positive Figure 2 Comparative expression patterns of various mxi1 mRNA isoforms in newborn and adult mouse tissues and developing mouse embryos. (a) Schematic of the probe employed in the RNase protection assay, which was derived from the mouse mxi1-WR cDNA. The radiolabeled probe (373 nt) was capable of being protected by the mxi1-WR transcripts (protected band 292 nt) as well as by the common regions of the mxi1-SRb and mxi1-SRa transcripts (protected bands of 137 and 133 nt, respectively). (b) RNase protection assays were performed upon total RNA (30 mg) isolated from the various newborn and adult mouse tissues shown (or tRNA as a control) using the 32 P-CTP radiolabeled riboprobe shown in (a). The protected bands for the mxi1-WR, mxi1-SRb, and mxi1-SRa transcripts (all shown with the same exposure time of 15 h) are marked by arrows. The undigested probe (probe) as well as 32 P-dCTP labeled Msp1-digested pBR322 DNA (ladder; molecular weights of the radiolabeled bands are shown on the right) were run in parallel. NB ¼ newborn, A ¼ adult. (c,d) Real Time RT-PCR analysis showing the relative amounts of the mouse mxi1-SRa (black bars) and SRb (gray bars) transcripts in selected adult tissues (c) and during embryogenesis (d). For units on the Y-axis, the value of 10 000 represents the amount of the respective transcripts that can be found in 300 ng of mouse prostate total RNA, the source of RNA used for the generation of the standard curves (see Materials and methods). e ¼ embryonic day A novel mxi1-encoded transcriptional repressor C Dugast-Darzacq et al control both were able to drive luciferase expression in a dose-dependent manner (data not shown). The sequence of the human MXI1-SRa minimal promoter region is presented in Figure 3c , with the localization of the transcriptional initiation sites as defined by RACE and of the putative transcription factor binding sites and regulatory elements shown (determined by MatInspector and visual inspection). Of note, this minimal promoter appears to be GC-rich, TATA-less, and CCAAT-less and to contain several consensus sequences for Initiator (Inr) elements, similar to what has been reported previously for the human MXI1-SRb promoter (Benson et al., 1999) .
Mxi1-SRa binds to the Sin3a and Sin3b adapter proteins with greater affinity than Mxi1-SRb As shown in Figure 1c above, the mxi1-SRa and mxi1-SRb transcript forms can encode highly related proteins that are 100% identical in their bHLH/LZ and carboxyl terminal portions but differ in their amino terminal ends. The Mxi1-SRa amino terminus is 103 aa long of which the latter 42 aa (aa 62-103) bear high homology (>70%) to the SID-containing 36 aa Mxi1-SRb amino terminus that engages Sin3 (Schreiber-Agus et al., 1995). Analysis of this homologous region of the Mxi1-SRa amino terminus indicates that it is conserved for many of the residues that have been shown to constitute the minimal SID of the Mad family members (and Mnt) van Ingen et al., 2004 ) (see Figure 1c ; minimal SID is underlined). Interestingly, molecular phylogenetic analyses have shown that the minimal SID of Mxi1-SRa bears greater resemblance to that of zebra fish Mxi1 (Schreiber-Agus et al., 1994) than to that of Mxi1-SRb, indicating that the SID of Mxi1-SRa may represent a more ancestral form (see Figure 4a) .
To confirm that the putative SID of the newly recognized Mxi1-SRa protein can indeed recruit Sin3 proteins, co-immunoprecipitation assays were performed upon 293T cells transfected with tagged versions of Mxi1-SRa, Mxi1-SRb, Sin3b or Sin3a (Figure 4b ; Sin3a co-immunoprecipitations not shown). In each case, the Sin3 protein tagged with a FLAG tag was immunoprecipitated with an anti-FLAG antibody, and the association of MYC-tagged Mxi1 isoforms was assessed by Western blotting of the immunoprecipitates with an anti-MYC tag antibody. As shown in Figure 4b , Mxi1-SRa, like Mxi1-SRb, was capable of interacting with Sin3b (and Sin3a; data not shown) in vivo (see lanes 2 and 4 in top panel for evidence of the interactions). Next, we employed quantitative yeast two hybrid assays to assess whether the differences in primary amino acid sequence between the SIDs of Mxi1-SRa and Mxi1-SRb could affect the affinity of these regions for the mammalian Sin3 proteins. For these directed yeast two-hybrid assays, the SID of Mxi1-SRb (SIDb; 36 amino terminal residues) or Mxi1-SRa (SIDa; corresponding 42 aa region; see above) was fused to the DNA binding domain (DBD) of bacterial LexA (baits), and the PAH2 þ PAH3 domains of Sin3a or Sin3b were fused to the transcriptional activation domain (TAD) of (Figure 4c) . Notably, this increased affinity for the Sin3 preys also was observed when the entire Mxi1-SRa amino terminus (103 aa region) was fused to the LexA DBD as the bait, suggesting that the 61 aa region preceding Mxi1-SRa's SID does not affect the ability of this SID to interact with Sin3 in these assays (data not shown). Taken together with the data presented in Figure 4a , the findings of Figure 4c may indicate that the divergence of the Mxi1-SRb minimal SID away from the ancestral version may have compromised partially its ability to engage Sin3.
Mxi1-SRa exhibits enhanced transcriptional repression properties relative to Mxi1-SRb
Based on the conserved ability of the Mxi1-SRa protein to recruit the Sin3 proteins and by extension Sin3-associated co-repressors, we predicted that this new isoform (and in particular its SID-containing amino terminal domain) would encode transcriptional repression activity as has been shown for Mxi1-SRb (Lee and Ziff, 1999; Yin et al., 2001 ) and other Mad family proteins (reviewed in Grandori et al., 2000; Baudino and Cleveland, 2001; Luscher, 2001 ). To assess this, the Mxi1-SRb and Mxi1-SRa amino termini (NTb and NTa) were fused in frame with the Gal4 DNA binding domain in mammalian expression vectors (Figure 5a) . These fusion proteins were tested for their ability to repress basal transcription of a luciferase reporter driven by a minimal tk promoter and four Gal4 binding sites after transfection into 293T cells (Figure 5a ). For these assays, basal transcription was defined as normalized luciferase counts after introduction of the Gal4 DBD portion only, and was set to 1.0. As expected, the Mxi1-SRa NT fusion protein was able to repress transcription effectively, and its effects were dose-responsive (range of repression 48-to 97-fold). Interestingly, the repression potential of the Mxi1-SRa NT was consistently higher than that of the Mxi1-SRb NT (range of repression for Mxi1-SRb NT was 11-to 71-fold) (Figure 5a ), despite equivalent expression levels of the effector proteins (data not shown). Similar results were obtained when fulllength versions of Mxi1-SRb and Mxi1-SRa were fused to the Gal4 DBD and employed as effectors in these assays, although it was more difficult to achieve equivalent protein expression levels in this case (data not shown).
To assess the transcriptional effects of the Mxi1-SRa protein in a more physiological context, we next tested its ability to bring about repression at E-box-containing reporters. Previous studies have shown that the ability of Mad/Mxi1 family proteins to repress at this E-box motif requires interactions both with the obligate DNA binding protein Max and with the Sin3/co-repressor complex (reviewed in Grandori et al., 2000; Baudino and Cleveland, 2001; Luscher, 2001 ). As such, first we confirmed that Mxi1-SRa was capable of interacting with Max by semiendogenous co-immunoprecipitations. As expected based on the identity of Mxi1-SRa's bHLH/LZ to that of Mxi1-SRb, Mxi1-SRa interacted with endogenous Max to an extent equal to or greater than Mxi1-SRb (Figure 5b) . In subsequent reporter assays in 293T cells, the repression of Mxi1-SRb at the E-box was observable, but modest at best (range of oneto two-fold) (Figure 5c and d ) similar to what has been reported previously (Lee and Ziff, 1999; Yin et al., 2001) . In contrast, full-length Mxi1-SRa consistently and reproducibly repressed basal activity of the E-box containing reporters 2.8-to 4.7-fold (Figure 5c and d) . Consistent with this finding, Mxi1-SRa also functioned as a more potent antagonist of Myc-mediated transactivation at the E-box, in that it was able to reverse this transactivation to a significant degree, while Mxi1-SRb could not, over a range of concentrations used ( Figure  5c and e and data not shown). Finally, removal of the 61 aa amino terminal extension of Mxi1-SRa did not affect (either negatively or positively) its ability to repress at the E-box (data not shown). Taken together, the results of the Gal4 heterologous and E-box based reporter assays suggest that Mxi1-SRa may be a more potent transcriptional repressor than Mxi1-SRb, this possibly relating to the findings of the quantitative yeast two hybrid analyses showing greater affinity of the SID of Mxi1-SRa, relative to that of Mxi1-SRb, for the Sin3 proteins (see Figure 4c above). Notably, a similar correlation between transcriptional response and affinity for Sin3 has been demonstrated recently for the Mad1 minimal SID and engineered mutants thereof that were designed on the basis of the Mad1 SID-Sin3 PAH2 solution costructure (Cowley et al., 2004 and references therein).
Discussion
Alternative leader exons/promoters leading to different mxi1 isoforms and their specific expression patterns It has been estimated that B50% of human genes have alternative splice forms, thus enhancing the complexity of the mammalian genome that now appears to have fewer genes than initially predicted (Modrek and Lee, 2002) . In many cases, the alternative mRNA isoforms give rise to proteins bearing distinct (and common) domains, which results in their separable biological activities and serves as a means for their functional regulation (Resch et al., 2004) . Efforts are now being expended to identify and characterize alternative splice forms on the global level and to assess their relative functional contributions to diversifying the human proteome Resch et al., 2004) .
Here, we show that the mouse and human mxi1 loci are subject to regulation by alternative exon usage, and describe a novel isoform called mxi1-SRa that joins the previously described mouse mxi1-SRb (formerly mxi1-SR) and mxi1-WR (Schreiber- Agus et al., 1995) . The identification of this isoform adds an additional layer of complexity to Mxi1 and the Mad/Mxi1 subfamily, and expands the list of mechanisms by which expression of members of the Myc/Max/Mad network is precisely regulated. All of the mxi1 mRNA isoforms described here result from alternative 5 0 -terminal exon (leader exon) incorporation, which in turn may relate to alternative promoter usage. Indeed, we have cloned the promoter for human MXI1-SRa, which is distinct from the one previously reported for MXI1-SRb (Benson et al., 1999 ) (see Figure 3) , and we predict that mxi1-WR will also be governed by its own promoter. The promoters for the two MXI1-SR forms appear to fall into the category of GC-rich, Initiator-containing, TATA-less, and CCAAT-less polymerase II promoters that are no longer believed to be restricted to 'housekeeping' genes (Smale, 1997) . This absence of the TATA box and presence of Initiator elements may allow for more fine-tuned regulation of these isoforms by tissue- Note that the repression effected by Mxi1-SRa is greater than that by Mxi1-SRb, at all dosages of the titration (150-600 ng/well of 150 000 cells). For each transfection point of the titration, Western blotting analysis of lysates probed with anti-MYC antibody showed that the levels of introduced, tagged Mxi1-SRb and Mxi1-SRa were equivalent (data not shown). (e) Graphic representation of the antagonistic effects of Mxi1-SRa and Mxi1-SRb proteins on Myc-mediated transactivation at the E-box reporter construct depicted in (c). One representative experiment of two performed, with each point done in triplicate in each experiment, is shown. The results are expressed as fold activation, with the activation of empty pcDNA3.1 set to 1.0. Note that Mxi1-SRa is able to reverse the transcriptional activation by Myc to a greater extent than Mxi1-SRb. Western blotting analysis of lysates probed with anti-MYC antibody showed that the levels of introduced, tagged Mxi1-SRb and Mxi1-SRa were equivalent (data not shown)
A novel mxi1-encoded transcriptional repressor C Dugast-Darzacq et al or developmental stage-specific regulators, with the presence or absence of specific regulators also dictating which isoforms will be generated. Said another way, production of the mxi1-SRa versus mxi1-SRb isoforms, with their distinct 5 0 open reading frame sequences, could reflect the specific transcriptional control of their individual promoter/enhancer regions, depending on cellular milieu (Ayoubi and Van De Ven, 1996; Landry et al., 2003) . Along these lines, we have shown by quantitative RT-PCR during mouse embryogenesis that there is a significant difference in the levels of mxi1-SRa relative to mxi1-SRb, with the former transcript being found in six-to 30-fold excess (Figure 2 ). More strikingly, in several of the adult mouse tissues tested, there appears to be preferential expression of one of these transcript forms over the other, that is, mxi1-SRa is predominantly expressed in intestine whereas mxi1-SRb is the major mxi1 transcript form in liver and kidney (Figure 2 ). Our cloning of the minimal promoter of mxi1-SRa (Figure 3) will aid in the future identification of more distal cis-regulatory elements, as well as trans-acting factors, that govern its tissue-specific pattern of expression.
With respect to the levels and tissue specificity of the mxi1-WR transcripts, as we have reported earlier (Schreiber-Agus et al., 1995) and here confirmed, this form is expressed at significantly lower levels than the two mxi1-SR forms. Notwithstanding, it remains to be determined whether the ratio between mxi1-WR and the mxi1-SR forms changes in certain spatiotemporal or disease-related contexts, and whether an increase in the mxi1-WR form can have functional consequences since it can encode a protein lacking the SID, a key domain of Mxi1 (Schreiber-Agus et al., 1995 and see more below). Finally, we have not addressed whether observed differences in steady state expression levels of mxi1-SRa, mxi1-SRb, and mxi1-WR result from differences in the degree of transcription initiation, message turnover, or both. In addition, it is possible that the different leader exons affect translational efficiency of the different isoforms. Owing to the difference in overall protein size and hence migration of Mxi1-SRa, Mxi1-SRb, and Mxi1-WR on SDS-PAGE, it will now be possible to employ Western blotting analysis with the anti-Mxi1 antibody (capable of detecting all three protein isoforms since it was raised to the conserved carboxyl terminus) to confirm and extend observations made on the mRNA level.
On a related note, our characterization of these mxi1 isoforms raises questions about the conclusions made about mxi1 expression patterns in previous reports, since in the majority of those studies the probes employed for Northern blotting analysis or in situ hybridization were ones that would recognize the isoforms collectively. It would be of great interest to revisit mxi1 expression patterns on the cellular level during embryogenesis with isoform-specific riboprobes or antibodies, or to employ similar tools to assess cancer-associated changes in MXI1 expression levels. Similarly, it would also be worthwhile to revisit studies that have examined MXI1 mutational status in various tumor types, and now take into consideration new coding exons (e.g. exon 1, that is B18.5 kb upstream of the MXI1 exons that were known previously) and new regulatory elements (e.g. the MXI1-SRa promoter region).
Functional diversity of Mxi1 isoforms imparted by alternative exon usage
Aside from giving rise to isoforms that exhibit differential expression patterns at the mRNA level, alternative promoter usage for mxi1-SRa and mxi1-SRb also leads to protein isoforms differing in their amino termini. More specifically, choice of the promoter preceding exon 1 leads to the generation of the Mxi1-SRa form with its 103 aa unique amino terminal region, and choice of the promoter preceding exon 2 leads to the generation of the Mxi1-SRb form with its 36 aa unique amino terminal region. As an aside, there are also alternative splicing choices operative, because exon 1 does not appear to splice into exon 3, despite the presence of a splice acceptor site in exon 3 that can be recognized by the splice donor in exon 2. The choice of the promoter seems then to be correlated with a specific splicing event, and the two processes together lead to the generation of two distinct (but very similar) SRa and SRb transcripts. This is not an isolated case, as the combination of alternative promoter usage and alternative splicing resulting in the generation of isoforms with distinct amino termini has many precedents (reviewed in Landry et al., 2003) .
Alternative splicing events have been postulated to be associated with exon creation and loss (Modrek and , which may provide a basis to explain how the SID-encoding exon 3 could have emerged. More specifically, this exon could have arisen from a duplication event of the SID-encoding exon 1 and its subsequent divergence throughout evolution. Along these lines, it is of interest that the zebra fish Mxi1 ortholog (Schreiber-Agus et al., 1994) has an amino terminal region, and more specifically a SID, of the Mxi1-SRa type (and indeed the characterization here of Mxi1-SRa allows us to definitively state that the published zMxi1 is truly an ortholog of Mxi1 as opposed to another Mad member). If we hypothesize that the SRa form is likely to be the ancestral form of Mxi1, the observation that mxi1-SRa is the predominant form expressed during embryogenesis is in line with the theory that isoforms containing regions that are conserved evolutionary are more likely to be the predominant ones (Boue et al., 2003; Modrek and Lee, 2003) . The question then becomes why mxi1-SRb is maintained as a distinct transcript, and one answer may relate to an asymmetry imparted upon mxi1-SRa and mxi1-SRb by their differential expression patterns (see above and Krakauer and Nowak, 1999) . However, we cannot rule out that the two SID-containing Mxi1 isoforms have nonoverlapping (and perhaps tissuespecific) functions as well. Preliminary evidence that this may be the case comes from the enhanced ability of the Mxi1-SRa isoform to recruit the Sin3 adapter proteins and to function as a transcriptional repressor in the Gal4 heterologous and E-box-based reporter assays (see Figures 4 and 5) . Moreover, at least at the level of competition with Myc for transcriptional regulation at E-box elements, the Mxi1-SRa isoform appears to function as a more potent Myc antagonist (Figure 5e ). Results from these and previous interaction and transcriptional repression studies suggest that the mxi1 genomic locus has the potential to encode a graded series of repressors, with Mxi1-SRa effecting strong, Mxi1-SRb effecting moderate, and Mxi1-WR (SID-less Mxi1) effecting weak repression activity (see also Schreiber-Agus et al., 1995; see also Lee and Ziff, 1999) , respectively. As such, the extent of repression of relevant, common downstream genetic targets could depend on the relative levels of these forms, which in turn would be dictated by spatiotemporal context.
Beyond this difference between Mxi1-SRa and Mxi1-SRb in potency of repression, it remains a possibility that the newly described Mxi1-SRa isoform may have functions encoded by its extended amino terminal domain that distinguish it from Mxi1-SRb. Alternatively, this domain may be playing a regulatory role in specific cellular or developmental contexts. The functions of this domain may not be readily apparent in assays such as the ones employed here which are transient in nature and involve overexpression of the various components, but may be realized in assays such as those that could compare the effects upon proliferation or differentiation of sustained loss or gain of these two isoforms. Along these lines, it is interesting to note that in previous reports that followed mxi1 expression during embryogenesis by in situ hybridization, the authors noted that mxi1, in contrast to some of the other mad family members, appeared to be expressed in both proliferating and differentiating cells (Hurlin et al., 1995; Queva et al., 1998) . However, since the probes employed there were unable to distinguish between the various isoforms, it is possible that that finding actually represents one mxi1 mRNA isoform being expressed in the former and another in the latter types of cells. In possible accord with this hypothesis is our observation that the mxi1-SRa form is the predominant form expressed during embryogenesis and in the adult intestine, both of which are marked by active proliferation. If distinct functions for Mxi1-SRa and Mxi1-SRb are revealed, perhaps the extended amino terminal domain of Mxi1-SRa could be altering its protein interaction profile or the spectrum of/activity at its downstream genetic targets. Of note, this type of scenario has been described recently for alternative isoforms of the Runx2 transcription factor that exhibit distinct transcriptional effects in modulating the TGFb 1 pathway (Sun et al., 2004) . The possibility of there being separable functions for Mxi1-SRa and Mxi1-SRb is now being addressed in studies directed at comparing these isoforms in more physiological contexts with alternative experimental systems.
Materials and methods

Plasmid construction
The full-length mxi1-SRa cDNA was amplified by RT-PCR upon mouse intestine total RNA using the 5 0 primer (5 0 -GCC AAGCTTGCGGACCCCCGTGCCTCCATGG -3 0 ) and the 3 0 primer (5 0 -GCCGCTCTAGACTAGGACGCGAAGGAG AGTTT-3 0 ), and then subcloned into pcDNA3.1 for the generation of the untagged mxi1-SRa expression construct. The corresponding, untagged mxi1-SRb expression construct was generated by transferring the mxi1-SRb cDNA clone (Schreiber-Agus et al., 1995) into pcDNA3.1. MYC-tagged versions of the mxi1-SRa, mxi1-SRb and myc were cloned into pcDNA3.1 or pJFE14. The ribovector for the RNase protection assays was a 373 base pair EcoRI/BglII fragment from the mouse mxi1-WR cDNA encoding part of its 5 0 UTR (exon 5) and its 5 0 coding region (exon 6) subcloned into pBluescript KS (Stratagene). The putative MXI1-SRa promoter region, cloned by PCR on human genomic DNA with the primers (5 0 -GCCAGATCTAGTGTTCTACTCTGTGGTAA G-3 0 ) and (5 0 -CCGAAGCTTGGGAGATTGAATGAACCT ACAG-3 0 ), was subcloned into the pGL3basic vector (Promega). The Gal4TK-luciferase control was a kind gift from Dr Kathryn Calame and the pRL-SV40 renilla luciferase plasmid was from Promega. The Sin3b-FLAG mammalian expression construct has been described previously (David et al., 1998) , as has the Sin3b yeast two hybrid prey (Schreiber-Agus et al., 1995; PAH2 and PAH3 domains; aa 111-374) and the SIDb bait (Schreiber-Agus et al., 1995; aa 2-32). The Sin3a prey was constructed by cloning a DNA fragment encoding the PAH2 and PAH3 domains of Sin3a (aa 183-541) downstream of the Gal4 TAD in pGAD424. The SIDa bait was constructed by cloning a DNA fragment encoding aa 62-99 of Mxi1-SRa downstream of the LexA DBD in pBTM116 (kind gift from Rolf Sternglanz). The pGal0 construct used for the Gal4 reporter assays was a kind gift of Dr Chi Dang, and the pGalNTb and pGal-NTa constructs were made by cloning aa 2-32 or aa 2-99, respectively, downstream of the Gal4 DBD (aa 1-147) in pGal0. The E-box driven luciferase reporter was a kind gift of Dr Robert Eisenman. Details of plasmid construction are available upon request.
Transient transfection, coimmunoprecipitation, and Western blotting 100 mm plates of human embryonic kidney (HEK) 293T cells were transfected with 5 mg of each of the appropriate expression constructs using Superfect (Qiagen), according to the manufacturer's instructions. After 48 h, whole-cell lysates were prepared by scraping the cells in 0.5 ml of JL buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 5 mM EGTA, in the presence of 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, 10 mg/ ml leupeptin). For the coimmunoprecipitations, lysates were precleared for 20 min with 30 ml of a 50% protein A-sepharose bead slurry (Sigma) and then incubated with the antibodybound sepharose beads for 2 h at 41C. The antibodies used for immunoprecipitation were FLAG mouse monoclonal antibody (M2, Sigma) and Max rabbit polyclonal antibody . Immunoprecipitated protein complexes were washed four times with 1 ml of NET buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 1 mM EDTA, in the presence of 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin) before resuspension in sodium dodecyl sulfate (SDS) sample buffer and resolution on 10 or 12% polyacrylamide gels. Western blotting was performed using standard procedures using the FLAG mouse monoclonal antibody (M2, Sigma), the MYC tag rabbit polyclonal antibody (Upstate #06-549), or the MYC mouse monoclonal antibody (Oncogene #OP-10). For detection of endogenous Mxi1-SRa and Mxi1-SRb proteins, total cell lysates or nuclear extracts (prepared as described in Kingston, 2004) from HeLa or 293T cells were fractionated by SDS-PAGE and probed with the MAD2 rabbit polyclonal antibody (Santa Cruz #sc-1042).
Reporter assays
For the Gal4 and E-box based reporter assays, HEK 293T cells were plated in six-well tissue culture dishes at a density of 1.5 Â 10 5 cells per well and transfected by calcium phosphate precipitation. Transfection mixtures contained 1 mg of plasmid per dish; 0.6, 0.3, or 0.15 mg of effector plasmid (Gal0, GalNTb, Gal-NTa, or MYC tagged version of Mxi1-SRb or Mxi1-SRa), 0.1 mg of the Gal4-TK-luciferase reporter or 0.2 mg (E-box) Â 4-luciferase reporter, 30 ng of the pRL-SV40 renilla luciferase plasmid, and the remainder empty pcDNA3.1. For the competition experiment at the E-box, 70 ng of MYCtagged myc construct and 600 ng of MYC-tagged versions of either Mxi1-SRb or Mxi1-SRa were used. The activities of the firefly and renilla luciferases were measured with the Dual Luciferase Reporter Assay System (Promega) using a TD-20/ 20 luminometer (Turner Designs). As renilla activity often was affected by the presence of our effectors, the data were represented as fold repression relative to empty vector based on luciferase counts after normalization for expression of the effector proteins. Levels of these effector proteins were assessed by Western blotting as above with the GAL4 DBD mouse monoclonal antibody (RK5C1, Santa Cruz) or the mouse monoclonal MYC antibody (Oncogene). Each transfection point was performed in triplicate 3-4 separate times.
For the human MXI1-SRa promoter study, 0.4 mg of either empty pGL3basic, pGL3basic carrying the region (187 bp) upstream of the transcription initiation sites for MXI1-SRa, or the Gal4-TK-luciferase reporter were transfected with 30 ng of pRL-SV40 renilla luciferase plasmid, and reporter activity was analysed as above. As there were no effector plasmids (that could affect renilla expression) for these reporter assays, the activity of the promoters was expressed as a ratio of luciferase to renilla. These transfection points were performed in triplicate two separate times.
Quantitative small-scale yeast two hybrid assays
The indicated baits and preys were cotransformed into the L40 yeast strain, and transformants were plated onto selective medium (lacking Trp, Leu, Lys and Ura). After 3 days, yeast colonies were grown in 10 ml of selective media to an OD of 1-1.2 at l ¼ 600 nm. Quantitative b-galactosidase assays were performed and b-galactosidase activity was expressed in Miller units as per Guarente (1983) . Western blotting analysis using the anti-LexA antibody (Invitrogen #460710) confirmed that the bait proteins were being expressed at similar levels.
Preparation of RNA, RNase protection, quantitative RT-PCR, and RACE-PCR
For the RNase protection assays, total RNA was prepared from newborn and adult mouse tissues by the LiCl/Urea method (Auffray and Rougeon, 1980) , and RNase protection assays were performed as described (Sambrook et al., 1989) using 30 mg of total RNA (or tRNA as a control) and 5 Â 10 5 cpm of 32 P-CTP labelled probe. Hybridizations were performed overnight at 681C. The probe and the protected fragments were resolved on 6% acrylamide/7 M urea sequencing gels and exposed to film. For the real time PCR analyses, RNA from mouse embryos and tissues was prepared using TriZOL (Invitrogen), and cDNAs were prepared with the Superscriptt II first strand kit (Invitrogen). Real time quantitative RT-PCR reactions were performed using the Light Cycler Fast Start DNA Master SYBR Green I kit (Roche) and the Smart Cycler apparatus (Cepheid). Each first strand cDNA sample was subjected to the following cycling program: 951C 10 min (951C 10 s, 601C 20 s, 721C 20 s)*45 cycles followed by a melting curve analysis to confirm the specificity of each amplicon, with the following isoformspecific upstream primers -mxi1-SRa primer 1s: 5 0 -CGCGG ATCCTTCAACACCAGCGAGAACTC-3 0 and mxi1-SRb primer 3s: 5 0 -AGTCGTCGTGGGACTGTAGC-3 0 combined with the common downstream primer 6as: 5 0 -GCTTCGAGT GCTGTAGCCGG-3 0 . Standard curves for mxi1-SRa and mxi1-SRb amplifications were generated using primers (1s þ 6as) or (3s þ 6as), respectively, on serially diluted first strand cDNAs from mouse prostate. Then, the samples indicated in Figure 2c and d were subject to real time PCR, and Ct values were obtained for each sample. The relative amount of each transcript to the other and throughout the time course of embryogenesis was then extrapolated from the appropriate standard curve to exclude contributions from possible differential efficiencies of the PCR reactions. The amounts of transcripts were normalized with the amount of input cDNA since a housekeeping gene that remained unchanged during development could not be identified (data not shown). 5 0 RACE reactions were carried out using the First-Choice RLM-RACE kit (Ambion). The specific primers used in combination with the supplied 5 0 primer to amplify the MXI1-SRa 5 0 -end from HeLa total RNA were: Outer: 5 0 -CGG GAATTCGCAGAAAAGTGTTGATGTGCTT-3 0 and Inner: 5 0 -CGGGAATTCTCACGAGTTCTCGCTGGTGTTG-3 0 .
Bioinformatics
The analysis of the various isoforms encoded by the mouse and human mxi1 genomic loci was aided by the UCSC Genome Bioinformatics website (http://genome.ucsc.edu/). MatInspector (Genomatix) (Quandt et al., 1995) was used to identify transcription factor binding sites in the minimal MXI1-SRa promoter. Molecular phylogenetic analysis of the minimal SIDs of the Mad family and Mnt proteins was performed with MultiAlign (Corpet, 1988) .
Note
GenBank Accession Number U24673 for exon 4-containing sequences. Exon 1 containing sequences are present in GenBank Accession Number BC064453, although we are fixing the initiator methionine as the methionine in frame and 25 aa upstream of the initiator methionine specified for that coding domain sequence. Note that there are exon 1-related sequences in GenBank Accession Number D31824 as well, although this mRNA appears to encode a protein initiating at a downstream methionine (aa 62 of our Mxi1-SRa) due to an omission of one C nucleotide that results in a frame shift. 
